nVector provides an advanced Adeno-Associated Virus (AAV) platform to accelerate gene therapy development for central nervous system (CNS) diseases. The company offers a proprietary capsid design library and GreenGlia Technology for precise targeting of glia and neuron cells. Additionally, nVector supports therapeutic pipelines with biomarker assay development and testing services, including a biologic diagnostic test for ALS.
Funding
$125K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gene therapy for central nervous system (CNS) diseases faces challenges due to the limited ability to target and access specific cells, as well as restricted gene expression. Current methods often struggle to effectively deliver therapeutic genes to the intended cells within the brain and spinal cord. This lack of precision and efficiency hinders the development of effective treatments for neurological disorders.
Solution
NVector utilizes its proprietary GreenGlia Technology to enhance gene therapy for CNS diseases by improving cell targeting and gene expression. The GreenGlia Technology employs adeno-associated virus (AAV) vectors to target specific glial and neuronal cells that were previously inaccessible. This targeted approach enables more effective delivery of therapeutic genes, potentially leading to improved outcomes for conditions such as Alzheimer's disease, Parkinson's disease, traumatic brain injury, and amyotrophic lateral sclerosis (ALS). NVector also offers CNS biomarker testing services and is developing a pipeline of gene therapies and clinical assays.
Target Audience
NVector's primary customers are biotechnology and pharmaceutical companies developing gene therapies for CNS diseases, as well as researchers and clinicians focused on neurological disorders.
Features
- GreenGlia Technology: AAV-based platform for targeted delivery of genes to specific glial and neuronal cells.
- Capsid Design Library: Identification and customization of viral capsids to meet specific needs.
- Biomarker Development: Customized CNS biomarker testing and development services.
- ALS Diagnostics: Development of a biologic diagnostic test for ALS.
- Therapeutic Pipeline: Development of treatments for ALS, Huntington’s, and Parkinson’s disease.